A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

导出原文传递

翻译打印收藏纠错

作者： Komrokji, Rami S. ^[1] ; Wei, Sheng ; Mailloux, Adam W. ; Zhang, Ling ; Padron, Eric ; Sallman, David ; Lancet, Jeffrey E. ; Tinsley, Sara ; Nardelli, Lisa A. ; Pinilla-Ibarz, Javier ; Epling-Burnette, Pearlie K. ; List, Alan F.

作者单位： MD Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA ^[1]

关键词 Hypomethyalting agents failure Immune Innate immunity MDSC T reg cells

发布时间 2019-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical lymphoma, myeloma & leukemia

2019年19卷3期

157-161页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes

Clinical lymphoma, myeloma & leukemia

相似文献

Clinical lymphoma, myeloma & leukemia

相关期刊

检索历史清除